Last reviewed · How we verify
Placebo every 2 weeks — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo every 2 weeks (Placebo every 2 weeks) — Eli Lilly and Company. Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo every 2 weeks TARGET | Placebo every 2 weeks | Eli Lilly and Company | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo every 2 weeks CI watch — RSS
- Placebo every 2 weeks CI watch — Atom
- Placebo every 2 weeks CI watch — JSON
- Placebo every 2 weeks alone — RSS
Cite this brief
Drug Landscape (2026). Placebo every 2 weeks — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-every-2-weeks. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing